COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBASTIC LEUKAEMIA, FROM A GREEK SOCIAL SECURITY SYSTEM PERSPECTIVE

被引：0
|
作者：
Kattamis, A. [1 ]
Avgitidou, A. [2 ]
Chatzopoulos, S. [2 ]
Markouri, A. [3 ]
Florini, S. [3 ]
Stafylas, P. [2 ]
机构：
[1] Univ Athens, Aghia Sophia Childrens Hosp, Dept Pediat 1, Athens, Greece
[2] HealThink, Thessaloniki, Greece
[3] Novartis, Athens A1, Greece
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN85
引用
收藏
页码：S452 / S452
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A CANADIAN SOCIETAL PERSPECTIVE
    Yang, H.
    Zhang, J.
    Hampe, M.
    VALUE IN HEALTH, 2018, 21 : S43 - S43
  • [2] Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain
    Santasusana, Josep Maria Ribera
    de Andres Saldana, Alejandra
    Garcia-Munoz, Nuria
    Gostkorzewicz, Joana
    Martinez Llinas, Diana
    Diaz de Heredia, Cristina
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 253 - 264
  • [3] Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective
    Wang, Xiao Jun
    Wang, Yi-Ho
    Ong, Matthew Jian Chun
    Gkitzia, Christina
    Soh, Shui Yen
    Hwang, William Ying Khee
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2022, 14 : 333 - 355
  • [4] BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA IN ENGLAND
    Hollmann, S.
    Painter, C.
    Hogan, A.
    Wickstead, R. M.
    Goyert, N.
    Patel, S.
    Slowley, A.
    Jousseaume, E.
    El Ouagari, K.
    Zhang, J.
    Jewitt, K.
    Ma, Q.
    VALUE IN HEALTH, 2018, 21 : S25 - S25
  • [5] Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland
    Maziar Moradi-Lakeh
    Mohsen Yaghoubi
    Patrick Seitz
    Mehdi Javanbakht
    Elisabeth Brock
    Advances in Therapy, 2021, 38 : 3427 - 3443
  • [6] Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland
    Moradi-Lakeh, Maziar
    Yaghoubi, Mohsen
    Seitz, Patrick
    Javanbakht, Mehdi
    Brock, Elisabeth
    ADVANCES IN THERAPY, 2021, 38 (06) : 3427 - 3443
  • [7] COST-EFFECTIVENESS OF TISAGENLECLEUCEL FOR ADULTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA : A CANADIAN SOCIETAL PERSPECTIVE
    Yang, H.
    Qi, C.
    Zhang, J.
    El Ouagari, K.
    VALUE IN HEALTH, 2018, 21 : S44 - S44
  • [8] Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan
    Wakase, Shiho
    Teshima, Takanori
    Zhang, Jie
    Ma, Qiufei
    Watanabe, Yoko
    Yang, Hongbo
    Qi, Cynthia Z.
    Chai, Xinglei
    Xie, Yanwen
    Wu, Eric Q.
    Igarashi, Ataru
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03): : 241.e1 - 241.e11
  • [9] Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States
    Qi, Cynthia Z.
    Bollu, Vamsi
    Yang, Hongbo
    Dalal, Anand
    Zhang, Su
    Zhang, Jie
    CLINICAL THERAPEUTICS, 2021, 43 (08) : 1300 - +
  • [10] AXICABTAGENE CILOLEUCEL AND TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN SPAIN: A COST-EFFECTIVENESS ANALYSIS
    Bastos-Oreiro, M.
    de las Heras, A.
    Presa, M.
    Casado, M. A.
    Pardo, C.
    Martin-Escudero, V
    Sureda, A.
    VALUE IN HEALTH, 2022, 25 (01) : S44 - S44
12345